GB9924992D0 - Pharmaceutical aerosol formulations - Google Patents

Pharmaceutical aerosol formulations

Info

Publication number
GB9924992D0
GB9924992D0 GBGB9924992.2A GB9924992A GB9924992D0 GB 9924992 D0 GB9924992 D0 GB 9924992D0 GB 9924992 A GB9924992 A GB 9924992A GB 9924992 D0 GB9924992 D0 GB 9924992D0
Authority
GB
United Kingdom
Prior art keywords
aerosol formulations
pharmaceutical aerosol
pharmaceutical
formulations
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9924992.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GBGB9924992.2A priority Critical patent/GB9924992D0/en
Publication of GB9924992D0 publication Critical patent/GB9924992D0/en
Priority to AU11411/01A priority patent/AU1141101A/en
Priority to PCT/EP2000/010306 priority patent/WO2001028535A2/en
Priority to AU13858/01A priority patent/AU1385801A/en
Priority to PCT/EP2000/010305 priority patent/WO2001028514A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
GBGB9924992.2A 1999-10-21 1999-10-21 Pharmaceutical aerosol formulations Ceased GB9924992D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9924992.2A GB9924992D0 (en) 1999-10-21 1999-10-21 Pharmaceutical aerosol formulations
AU11411/01A AU1141101A (en) 1999-10-21 2000-10-19 Pharmaceutical aerosol formulations comprising s-salmeterol
PCT/EP2000/010306 WO2001028535A2 (en) 1999-10-21 2000-10-19 Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
AU13858/01A AU1385801A (en) 1999-10-21 2000-10-19 Pharmaceutical formulations
PCT/EP2000/010305 WO2001028514A1 (en) 1999-10-21 2000-10-19 Pharmaceutical aerosol formulations comprising s-salmeterol

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9924992.2A GB9924992D0 (en) 1999-10-21 1999-10-21 Pharmaceutical aerosol formulations

Publications (1)

Publication Number Publication Date
GB9924992D0 true GB9924992D0 (en) 1999-12-22

Family

ID=10863173

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9924992.2A Ceased GB9924992D0 (en) 1999-10-21 1999-10-21 Pharmaceutical aerosol formulations

Country Status (3)

Country Link
AU (2) AU1385801A (en)
GB (1) GB9924992D0 (en)
WO (2) WO2001028535A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020387A1 (en) * 2000-08-31 2002-06-24 Glaxo Group Ltd USE OF A COMBINATION OF SALMETEROL AND FLUTICASONE
GB0021927D0 (en) * 2000-09-07 2000-10-25 Glaxo Group Ltd Use of pharmaceutical combination
GB0106031D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Use
GB0124523D0 (en) * 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
US20060293293A1 (en) * 2003-05-22 2006-12-28 Altana Pharma Ag Salmeterol and ciclesonide combination
JP4778053B2 (en) * 2005-07-14 2011-09-21 リセラ，インコーポレイテッド Extended release lipolytic formulation for topical adipose tissue treatment
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
TR201000685A2 (en) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Pharmaceutical preparations containing salmeterol and fluticasone.
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
BR9604977A (en) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Metered dose inhaler metered dose inhaler system and use
US6254882B1 (en) * 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol

Also Published As

Publication number Publication date
AU1141101A (en) 2001-04-30
WO2001028535A3 (en) 2002-01-10
AU1385801A (en) 2001-04-30
WO2001028514A1 (en) 2001-04-26
WO2001028535A2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
IL139087A0 (en) Pharmaceutical aerosol formulation
HUP0202235A3 (en) Preserved pharmaceutical formulations
AU6310000A (en) Aerosol formulations
IL155088A0 (en) Medicinal aerosol formulations
AU6715600A (en) Pharmaceutical formulations
HK1045102A1 (en) Pharmaceutical formulations
GB9924992D0 (en) Pharmaceutical aerosol formulations
GB9909154D0 (en) Pharmaceutical formulation
EP1221941A4 (en) Powder pharmaceutical formulations
GB9906126D0 (en) Pharmaceutical formulations
GB9930578D0 (en) Pharmaceutical formulations
GB9926251D0 (en) Pharmaceutical formulation
GB0014849D0 (en) Pharmaceutical aerosol formulation
GB9921289D0 (en) Pharmaceutical aerosol formulation
GB9903177D0 (en) Pharmaceutical formulations
GB9905983D0 (en) Pharmaceutical formulations
GB9911826D0 (en) Pharmaceutical formulations
GB0014881D0 (en) Pharmaceutical aerosol formulation
GB9808152D0 (en) Pharmaceutical aerosol formulation
GB9814709D0 (en) Pharmaceutical aerosol formulation
SI1073417T1 (en) Pharmaceutical aerosol formulation
GB0024711D0 (en) Medicinal aerosol formulations
GB0128582D0 (en) Pharmaceutical aerosol formulations
GB9927685D0 (en) Pharmaceutical formulation
GB9917775D0 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)